首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
【24h】

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

机译:前置中枢神经系统后移植后淋巴移植症:国际中枢神经系统淋巴瘤合作组报告。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes. METHODS: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNS-PTLD without evidence of systemic PTLD were investigated retrospectively. RESULTS: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival. CONCLUSIONS: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.
机译:背景:原发性中枢神经系统(CNS)移植后淋巴抑制性疾病(PCNS-PTLD)是固体器官移植的罕见并发症。本研究的目的是定义这种疾病的临床,放射学和病理特征,并探讨治疗对患者结果的影响。方法:作者审查了PCNS-PTLD案例的国际初级CNS淋巴瘤协作组的参与机构的数据库。回顾性地研究了无病理证实的PCNS-PTLD的34例病理证实的PCNS-PTLD。结果:从移植到PCNS-PTLD诊断的中位时间为4.4岁。疾病通常是多灶性的,涉及大脑的任何位置,但在脑半球中最常见,通常在皮质片段或基础神经节。射线照相上,所有病变均匀增强或以环增强图案增强。需要在大多数患者中建立诊断所需的脑活组织检查。大多数患者患有单声道的,Epstein-Barr病毒(EBV) - B细胞源性疾病。无论治疗类型如何,反应率都很高,中位存活率为47个月。年龄是预测生存的唯一因素。结论:目前的研究表明,PCNS-PTLD通常是EBV诱导的B细胞淋巴瘤,其响应于许多患者的良好生存治疗。强烈考虑应当考虑一种积极的组织确认和化疗或放疗的诊断和治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号